164 related articles for article (PubMed ID: 30182361)
1. Peripheral T and B lymphocytes do not correlate with Graves' orbitopathy.
Ionni I; Rotondo Dottore G; Marinò M
J Endocrinol Invest; 2018 Nov; 41(11):1355-1356. PubMed ID: 30182361
[No Abstract] [Full Text] [Related]
2. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression.
Salvi M; Vannucchi G; Campi I; Rossi S; Bonara P; Sbrozzi F; Guastella C; Avignone S; Pirola G; Ratiglia R; Beck-Peccoz P
Eur J Endocrinol; 2006 Apr; 154(4):511-7. PubMed ID: 16556712
[TBL] [Abstract][Full Text] [Related]
3. Peripheral blood T lymphocyte sensitisation against calsequestrin and flavoprotein in patients with Graves' ophthalmopathy.
Nguyen B; Gopinath B; Tani J; Wescombe L; Wall JR
Autoimmunity; 2008 Aug; 41(5):372-6. PubMed ID: 18568642
[TBL] [Abstract][Full Text] [Related]
4. Can autoimmunity against calsequestrin explain the eye and eyelid muscle inflammation of thyroid eye disease?
Gopinath B; Wescombe L; Nguyen B; Wall JR
Orbit; 2009; 28(4):256-61. PubMed ID: 19839885
[TBL] [Abstract][Full Text] [Related]
5. B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family.
Nielsen CH; El Fassi D; Hasselbalch HC; Bendtzen K; Hegedüs L
Expert Opin Biol Ther; 2007 Jul; 7(7):1061-78. PubMed ID: 17665994
[TBL] [Abstract][Full Text] [Related]
6. Increase of peripheral B lymphocytes in Graves' disease.
Mori H; Amino N; Iwatani Y; Kabutomori O; Asari S; Motoi S; Miyai K; Kumahara Y
Clin Exp Immunol; 1980 Oct; 42(1):33-40. PubMed ID: 6970099
[TBL] [Abstract][Full Text] [Related]
7. Graves' disease and Graves' orbitopathy following COVID-19.
Lanzolla G; Marcocci C; Marinò M
J Endocrinol Invest; 2021 Sep; 44(9):2011-2012. PubMed ID: 33964007
[No Abstract] [Full Text] [Related]
8. New immunomodulators in the treatment of Graves' ophthalmopathy.
Salvi M; Vannucchi G; Campi I; Currò N; Beck-Peccoz P
Ann Endocrinol (Paris); 2008 Apr; 69(2):153-6. PubMed ID: 18417090
[TBL] [Abstract][Full Text] [Related]
9. Potential utility of rituximab for Graves' orbitopathy.
Salvi M; Vannucchi G; Beck-Peccoz P
J Clin Endocrinol Metab; 2013 Nov; 98(11):4291-9. PubMed ID: 24009135
[TBL] [Abstract][Full Text] [Related]
10. Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trials.
Banga JP; Nielsen CH; Gilbert JA; El Fassi D; Hegedus L
Thyroid; 2008 Sep; 18(9):973-81. PubMed ID: 18752425
[TBL] [Abstract][Full Text] [Related]
11. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
[TBL] [Abstract][Full Text] [Related]
12. CD8+CD28-lymphocytes in peripheral blood and serum concentrations of soluble interleukin 6 receptor are increased in patients with Graves' orbitopathy and correlate with disease activity.
Slowik M; Urbaniak-Kujda D; Bohdanowicz-Pawlak A; Kapelko-Slowik K; Dybko J; Wolowiec D; Jazwiec B; Daroszewski J
Endocr Res; 2012; 37(2):89-95. PubMed ID: 22489922
[TBL] [Abstract][Full Text] [Related]
13. Clinical Implications of Immunoglobulin G4 to Graves' Ophthalmopathy.
Yu SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Thyroid; 2017 Sep; 27(9):1185-1193. PubMed ID: 28805160
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical studies using immunized Guinea pig sera with features of anti-human thyroid, eye and skeletal antibody and Graves' sera.
Molnár I; Szombathy Z; Kovács I; Szentmiklósi AJ
J Clin Immunol; 2007 Mar; 27(2):172-80. PubMed ID: 17243008
[TBL] [Abstract][Full Text] [Related]
15. Increased percentage of L-selectin+ and ICAM-1+ peripheral blood CD4+/CD8+ T cells in active Graves' ophthalmopathy.
Pawlowski P; Mysliwiec J; Stasiak-Barmuta A; Bakunowicz-Lazarczyk A; Gorska M
Folia Histochem Cytobiol; 2009; 47(1):29-33. PubMed ID: 19419934
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for Graves' ophthalmopathy.
Salvi M
Curr Opin Endocrinol Diabetes Obes; 2014 Oct; 21(5):409-14. PubMed ID: 25105999
[TBL] [Abstract][Full Text] [Related]
17. CD4+ T cells and the Th1/Th2 imbalance are implicated in the pathogenesis of Graves' ophthalmopathy.
Xia N; Zhou S; Liang Y; Xiao C; Shen H; Pan H; Deng H; Wang N; Li QQ
Int J Mol Med; 2006 May; 17(5):911-6. PubMed ID: 16596280
[TBL] [Abstract][Full Text] [Related]
18. CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves' disease and modulates clinical phenotype of disease.
Pawlak-Adamska E; Frydecka I; Bolanowski M; Tomkiewicz A; Jonkisz A; Karabon L; Partyka A; Nowak O; Szalinski M; Daroszewski J
Endocrine; 2017 Jan; 55(1):186-199. PubMed ID: 27638540
[TBL] [Abstract][Full Text] [Related]
19. Optimal management of Graves orbitopathy: a multidisciplinary approach.
Soeters MR; van Zeijl CJ; Boelen A; Kloos R; Saeed P; Vriesendorp TM; Mourits MP
Neth J Med; 2011; 69(7):302-8. PubMed ID: 21934174
[TBL] [Abstract][Full Text] [Related]
20. Lymphocyte subpopulations in Graves' ophthalmopathy.
Felberg NT; Sergott RC; Savino PJ; Blizzard JJ; Schatz NJ; Amsel J
Arch Ophthalmol; 1985 May; 103(5):656-9. PubMed ID: 3873236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
